SOURCE: Crucell N.V.

November 12, 2007 02:10 ET

Crucell Announces Marketing and Distribution Deal with Sanquin

LEIDEN, NETHERLANDS--(Marketwire - November 12, 2007) - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced the start of a marketing and distribution agreement with Sanquin, the Dutch Blood Supply Foundation.

Under the terms of the agreement, Crucell will get exclusive distribution rights of Cofact® - Sanquin's prothrombin complex of blood factors II, VII, IX and X which is currently in MRP (mutual recognition procedure) registration - in a number of Crucell's key markets including Norway, Sweden, Denmark, Spain and Italy. Crucell will also have a right of first refusal for China, Korea and a number of Eastern European countries.

Crucell's Chief Executive Officer, Ronald Brus said: "This deal complements the distribution agreement that is in place with Talecris since April 2007. Both deals are in line with our protein strategy to enhance Crucell's market presence with plasma derived products."

Cofact® is a market leading product in the Netherlands and Belgium with approximately EUR 10 million in sales annually in these countries alone. The European market is estimated to amount up to EUR 100 million. Cofact® is aimed at promoting blood-clotting for patients treated with anti-coagulants that have bleeding as a result of trauma or urgent surgery, or for prophylactically treating patients with Factor II, VII and X deficiencies.

About Crucell

Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminium-free hepatitis A vaccine on the market. The Company has a broad pipeline, with several products based on its unique PER.C6® production technology in development. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, Novartis, Wyeth and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit www.crucell.com.

Forward-looking statements

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on June 13, 2007, and the section entitled "Risk Factors". The Company prepares its financial statements under International Financial Reporting Standards (IFRS) with reconciliation to the generally accepted accounting principles in the United States (US GAAP).

For further information please contact:


Media:                                Investors/Analysts:

Barbara Mulder                        Oya Yavuz
Director Corporate Communications     Director Investor Relations
Tel: +31-(0) 71-519 7346              Tel. +31-(0) 71-519 7064
press@crucell.com                     ir@crucell.com
www.crucell.com                       www.crucell.com

PDF file: http://hugin.info/132631/R/1167644/229104.pdf



Copyright © Hugin ASA 2007. All rights reserved.

Contact Information